[Ulipristal acetate, 5mg: a new alternative]

Area of Science:

• Gynecology
• Reproductive Medicine
• Pharmacology

Background:

• Uterine fibroids affect nearly 50% of women, causing significant health issues like bleeding, pain, and infertility.
• While surgery is effective, less invasive options like uterine artery embolization and thermal ablation are emerging.
• Medical treatments, including GnRH analogues and selective progesterone receptor modulators (SPRMs), are also developing.

Purpose of the Study:

• To evaluate the efficacy and safety of ulipristal acetate (UA) as a treatment for uterine fibroids.
• To compare UA with placebo and leuprolide acetate (LA) in managing fibroid symptoms and size.

Main Methods:

• Phase III randomized clinical trials (PEARL I and II) were conducted.
• Ulipristal acetate (UA) was administered and compared against placebo and leuprolide acetate (LA).
• Efficacy was assessed by fibroid size reduction, uterine volume, and bleeding control. Safety and side effects were monitored.

Main Results:

• Ulipristal acetate (UA) demonstrated significant efficacy in controlling bleeding and reducing fibroid size compared to placebo.
• UA showed comparable efficacy to leuprolide acetate (LA) in managing fibroid symptoms.
• UA was associated with fewer side effects than LA, and overall safety and tolerance were satisfactory.
• Amenorrhea was observed in most patients treated with UA.

Conclusions:

• Ulipristal acetate (UA) is an effective and safe medical treatment for uterine fibroids, particularly in the preoperative setting.
• UA offers a favorable side effect profile compared to leuprolide acetate (LA).
• UA represents a significant advancement in the medical management of uterine fibroids with potential for further applications.